sermorelin

Trade name: geref

BiologicalapprovedOrphan Drug FDA

Approved

Dec 28, 1990

Sermorelin, a 29 amino acid analog of human growth hormone-releasing hormone (GHRH), is the shortest synthetic peptide with a full biological activity of GHRH which is used as a diagnostic agent to assess growth hormone (GH) secretion for the purpose of diagnosing growth hormone deficiency. Intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary. Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion. Hormone responses to intravenous sermorelin appear to be a rapid and relatively specific test for the diagnosis of growth hormone deficiency. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1980s

  1. Sep 14, 1988

    Orphan Drug Designation

1990s

  1. Dec 28, 1990

    Merck Serono — Earliest FDA Approval

  2. Dec 28, 1990

    Merck Serono — NDA Organization

  3. Dec 28, 1990

    Merck Serono — NDA Secondary Org

Indications

Mechanism of action

Approval history

  • approvedDec 28, 1990

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • geref
  • geref
  • geref
  • sermorelin
  • sermorelin
  • sermorelin
  • sermorelin
  • sermorelin
  • sermorelin
  • sermorelin
  • sermorelin acetate
  • sermorelin acetate
  • sermorelin acetate
  • sermorelin acetate
  • sermorelin acetate
  • sermorelin acetate
  • sermorelin acetate
  • somatoliberin

Organizations

Marketing (3)

OrganizationOrg typeRelationshipDate
Merck SeronoFor profitNDADec 28, 1990
Merck SeronoFor profitNDA2Dec 28, 1990
Merck SeronoFor profitSYNSep 26, 1997